$ALLR

Allarity Therapeutics, Inc.

Allarity Therapeutics is a clinical-stage precision medicine pharmaceutical company developing cancer treatments for patients with high unmet medical need. It is focused on stenoparib, an investigational drug that inhibits PARP and tankyrases, and on developing the stenoparib DRP® companion diagnostic to help identify patients likely to benefit from treatment. Allarity is evaluating stenoparib in phase 2 studies for ovarian cancer and, in combination with temozolomide, for relapsed small cell lung cancer. The company’s DRP® platform uses gene-expression analysis to develop drug-specific diagnostics. Allarity also provides DRP® analysis and gene-expression services to external biotech clients. Its laboratory generated $0.3 million of revenue in 2025. Allarity’s principal executive offices are in Tarpon Springs, Florida.

3
2
3

No SEC Form 4 filings for $ALLR in the last 30 days.

See all $ALLR insider activity →

Allarity Therapeutics, Inc. (ALLR): Entry into a Material Definitive Agreement

Allarity Therapeutics, Inc. (ALLR) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Exhibit 99.1 Allarity Therapeutics Expands Phase 2 Stenoparib Trial to Three Ovarian Cancer Patient Cohorts Investigator-supported move capitalizes on strong enrollment momentum and encouraging early clinical observations Adds platinum-refractory patients as well as those with ha

ALLR sentiment & insider activity

Over the past 7 days, AlphAI's AI scored 8 news stories mentioning ALLR (Allarity Therapeutics, Inc.). Coverage has been balanced: 3 bullish, 2 neutral, and 3 bearish.

Recent ALLR coverage spans corporate actions, financial news and earnings.

What's driving ALLR

AlphAI scores every news story that mentions ALLR with an AI model for sentiment and relevance, and aggregates insider trades from Allarity Therapeutics, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.

News on $ALLR

Score
$ALLRMedClinical / regulatory· trial start

Allarity Therapeutics, Inc. (ALLR): Entry into a Material Definitive Agreement

Allarity Therapeutics, Inc. (ALLR) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Exhibit 99.1 Allarity Therapeutics Expands Phase 2 Stenoparib Trial to Three Ovarian Cancer Patient Cohorts Investigator-supported move capitalizes on strong enrollment momentum and encouraging early clinical observations Adds platinum-refractory patients as well as those with ha

$ALLRMedContract· supplier

Allarity Therapeutics, Inc. (ALLR): Entry into a Material Definitive Agreement

Allarity Therapeutics, Inc. (ALLR) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Exhibit 99.1 Allarity Therapeutics Secures First Commercial Agreement Under New CLIA Laboratory Services Strategy, Establishing Potential Path to Additional Recurring Revenue - Agreement complements revenue from standard gene expression and DRP® services - Development and validat

$ALLRLowOffering· $6M · terminated

Allarity Therapeutics, Inc. (ALLR): Termination of a Material Definitive Agreement

Allarity Therapeutics, Inc. (ALLR) filed an SEC Form 8-K — Termination of a Material Definitive Agreement. Item 1.02 Termination of a Material Definitive Agreement. Termination of Common Stock Purchase Agreement On October 28, 2026, Allarity Therapeutics, Inc. (the “Company”) terminated the Common Stock Purchase Agreement, dated January 28, 2026 (the “Purchase Agreement”), by and betw

Related tickers